Arex Industries Limited Overview
Arex Industries is a promoter-controlled Indian micro-cap that designs and weaves branded identification labels: woven labels in satin and taffeta, plus printed labels. Its customers are apparel, home-textile and footwear manufacturers. Founded in 1989 by Dinesh Bilgi and now run jointly with his sons Neel and Chirag, it operates two Gujarat plants. The first is a computerised weaving unit at Chhatral near Ahmedabad. The second is a captive-style unit at Anjar, Kutch, built beside Welspun's home-textile campus under a 10-year agreement in which Welspun committed to take at least 75% of that plant's capacity. CARE describes Arex as one of the larger organised domestic players in a niche, fragmented segment dominated by unorganised producers. Revenue has held at about INR 45–54 crore for five years, EBITDA margins sit in the mid-teens, and capacity utilisation runs at 40–60%. The investment case therefore depends on whether the company can lift utilisation, grow its small but fast-rising export book, and convert a planned move into packaging materials into growth.
What the company does
Arex makes garment and textile identification labels: the woven or printed tags sewn into apparel, bed linen, towels and footwear to carry the brand name, size, care instructions and other trim information. CARE (June 2025 and July 2026) describes the core product as woven labels of satin and taffeta quality in white or black warp-base, made in shapes, sizes and colours specified by each customer, alongside a line of printed labels.
The company's legacy product page says it can supply about 414 million woven labels a year. The labels can be woven up to 500 mm wide in up to 12 colours, with coloured warp-bases available on custom orders. Edge options are ultrasonic cutting, hot-slit edges on broad looms, and soft edges on needle looms. Finishing options include end fold, centre fold, mitre fold, Manhattan fold, starching, special coatings, self-adhesive and thermo-adhesive backings, laser cutting, die cutting, filled-in labels and "comfort soft" finishes.
Company's own description
In BSE filings and its corporate profile, the company describes itself as a manufacturer and trader of woven and printed labels. It emphasises translating customer requirements into weaving patterns, a computerised plant using imported machinery, international quality standards, and reliable delivery against tight schedules. The FY2026 Integrated Annual Report's MD&A could not be accessed directly. Its key themes, as captured in secondary summaries, were softer domestic demand, sharply higher exports, rising employee costs, and an amendment to the Memorandum of Association adding packaging materials as a business object.
Independent characterisation
Arex is a business-to-business, made-to-order textile trim converter. Its economics follow from four features:
-
Design-led, short-run manufacturing. Every order starts with design work (CAD artwork translated into weave patterns), sampling and approval. This creates mild switching costs once a brand's label is approved. It also means a long order-to-cash cycle and heavy inventory, because Arex keeps stocks of many coloured yarns so it can respond to any brand's palette. CARE reported inventory periods of 68 days in FY25 and 87 days in FY26.
-
Low share of customer wallet, low pricing power. Labels are a tiny fraction of a garment's cost. Buyers are price-sensitive, and the unorganised sector caps price increases. CARE repeatedly notes that Arex has limited ability to pass on yarn price increases, which track cotton and crude oil.
-
Capital intensity relative to revenue. Weaving looms (airjet, rapier and needle) and finishing lines carry a large fixed asset base. At 40–60% utilisation, fixed-asset turnover was only about 0.47x in FY26 and 0.49x in FY25 (CARE). Depreciation of about INR 4.1–4.4 crore a year consumes more than half of EBITDA.
-
Anchor-customer dependence. The Anjar plant is effectively dedicated to Welspun under a minimum 75% offtake agreement. The top ten customers were 57% of operating income in FY25 and 60% in FY24 (CARE).
Revenue model
| Revenue type | Share | Comment |
|---|---|---|
| Manufactured product sales (woven labels) | Majority, exact split not publicly disclosed | Core business. Billed per piece or per batch on job-specific pricing. |
| Manufactured product sales (printed labels) | Minority, not publicly disclosed | Installed capacity 15,000 million pick metres (CARE) |
| Traded goods (labels / trims) | — | The company describes itself as "manufacturing & trading" |
| Services / subscription / licensing | Nil | No recurring service or licensing revenue |
| Power (wind) | Captive. Not separately disclosed as revenue. | Two windmills of 1.60 MW aggregate at Porbandar (CARE). Likely offsets grid power cost. |
Value chain position
Arex sits between yarn suppliers (synthetic polyester and cotton tape/yarn) and garment, home-textile and footwear manufacturers. Those manufacturers in turn serve domestic and global brands and retailers. Label specifications are often set by the brand owner, while the purchase order is placed by the garment or home-textile maker. Arex's relationship is therefore usually with the converter, such as Welspun or the Tirupur knitwear exporters, rather than with the end brand.
Customer types and end-markets
| End-market | Evidence | Demand character |
|---|---|---|
| Ready-made garments (domestic and export-oriented) | CARE: demand arises mainly from apparel / RMG | Cyclical. Follows domestic consumption and Indian apparel exports. |
| Home textiles (towels, bed linen) | CARE: home textiles a key segment; Welspun is the anchor customer | Strongly linked to US retail demand. CARE noted the FY23–FY24 slowdown and recovery from Q4 FY24. |
| Footwear | CARE: footwear is an additional end-market | Smaller share |
| Export customers | Exports INR 2.97 crore in FY26 vs INR 0.75 crore in FY25 (+311%) | Nascent but growing |
Financial Narrative
Sources: Screener.in (C-MOTS data compiled from BSE filings); CARE Ratings PRs of 27-Jun-2025 and 06-Jul-2026 (audited FY23–FY25, abridged FY26); FY26 audited results as summarised by ScanX (21-May-2026 and 24-Aug-2026); FinancialFilings.com (FY26 headline figures). "Derived" means computed by this analyst from disclosed figures. "Rounded" means Screener's whole-crore presentation.
Income statement (INR Cr)
Gross profit is not reported by the company in a comparable form (Ind AS presentation by nature of expense). Simply Wall St's TTM "gross profit" of INR 35.06 crore is revenue minus material cost. It is not comparable to a conventional gross margin and is excluded.
Margin profile (%)
Revenue growth: the four-year CAGR from FY2022 to FY2026 is −2.0% (derived). The five-year CAGR from FY2021 (INR 40.88 crore) to FY2026 is +4.0%, matching Screener's 3.96%. The ten-year sales CAGR is about 4% (Screener). Profit CAGR is −7% over ten years and +28% over five years, flattered by the FY2021 loss base.
Quarterly trend (INR Cr) — last 13 quarters
Source: Screener quarterly table (from BSE result PDFs). Q1 FY27 PBT includes the INR 9.54 crore keyman insurance maturity, classified as an exceptional item. Ordinary PBT for Q1 FY27 was INR 2.24 crore versus INR 0.34 crore in Q1 FY26 (ScanX; Business Standard).
Small discrepancies across sources:
-
Q4 FY26 revenue is INR 12.38 crore (Screener) versus INR 12.37 crore in the ScanX summary of the audited result. Some outlets show INR 12.43 crore total income.
-
One aggregator (IndMoney) reports Q1 FY27 "revenue" of INR 23.82 crore. This appears to add the exceptional gain to sales and conflicts with the filed figure of INR 14.28 crore.
-
One ScanX summary describes Q1 FY26 as a net loss of INR 24.69 lakh. It was a profit of INR 24.69 lakh.
-
A ScanX Q2 FY26 summary mislabels lakh figures as "crore".
Commentary on income statement trends. Arex has been range-bound. Revenue peaked at INR 53.75 crore in FY22, a post-COVID restocking year. It fell 16% in FY23 when US retailers destocked home textiles and Welspun-linked volumes slowed (CARE notes the global home-textile slowdown in FY23–FY24). It recovered to about INR 51 crore in FY24–FY25 and slipped 2.9% to INR 49.64 crore in FY26 on weaker domestic demand, partly offset by a fourfold rise in exports.
The more important trend is margin compression. EBITDA margin fell from 20.9% (FY22) to 14.6% (FY26). CARE attributes the FY25 and FY26 declines mainly to higher employee costs; Q3 FY26 employee expenses rose 18.9% YoY. Because depreciation (about INR 4.1–4.4 crore) and interest (about INR 1.0–1.3 crore) are largely fixed, each point of EBITDA margin moves PBT disproportionately. The 1.3-point margin fall in FY26 cut PBT by 48%.
FY25 earnings were also helped by unusually high other income of INR 0.69 crore against INR 0.06 crore in FY26, which exaggerates the FY26 decline.
Q1 FY27 is a genuine operating inflection as well as a one-off. Revenue rose 26.7% YoY and OPM recovered to 23.5%, the highest since Q3 FY24. One quarter does not establish a trend, but it is the first sign of the operating leverage the plant base allows if utilisation rises.
Balance sheet (INR Cr, as at 31 March)
The "total debt" row shows 0 for FY2022 because CARE's gearing figure for that year was not available in sources accessed. Use the Screener row (INR 23 crore) for FY22. Receivables are disclosed in sources accessed only for FY25 and FY26; zeros in earlier years mean "not available", not nil.
Cash and liquidity
Sources: ScanX summary of FY26 annual report; CARE PR 06-Jul-2026. FY25 non-current borrowings are derived as total debt minus current borrowings and are approximate. All term loans fall due in FY27, so they have been reclassified to current liabilities, which pushed the current ratio to 1.0x (CARE).
Working capital (current assets minus current liabilities) is not reported directly. CARE's current ratio of 1.0x implies working capital of about zero at FY26-end after the term-loan reclassification. Screener reports working-capital days of 30 (FY25) and −1 (FY26).
Commentary on the balance sheet. Total assets have shrunk from INR 68 crore (FY19 peak) to INR 45 crore (FY26) as the Anjar asset base depreciates and debt is repaid. Borrowings fell from about INR 35 crore (FY19) to about INR 10.5 crore (FY26).
The FY25 buyback of 3.6 lakh shares at INR 195 (about INR 7.02 crore, plus buyback tax) was paid from free reserves. It cut net worth from INR 31.61 crore to INR 25.67 crore. Gearing therefore rose from 0.33x to 0.48x, also helped by directors' unsecured loans. In FY26 gearing improved to 0.38x as those unsecured loans were withdrawn (CARE).
There is no goodwill: the company has never made an acquisition. Book value per share was about INR 77 at FY26-end (Screener), before the Q1 FY27 insurance gain of INR 8.81 crore after tax. That gain would add roughly INR 24 per share to book value, net of the INR 0.90 crore dividend paid after the September 2026 AGM.
Cash flow (INR Cr)
The FY26 dividend (INR 0.90 crore) falls in FY27 cash flows. The FY25 CFO figure has two versions: CARE gives INR 8.67 crore, while the ScanX summary of the audited cash-flow statement gives INR 8.905 crore. The difference is likely pre-tax versus post-tax operating cash flow.
Commentary on cash flow. Cash conversion is the company's best financial attribute. CFO exceeded reported operating profit in every one of the last five years (103–126%), because depreciation is large and working capital has been released (debtor days fell from 103 in FY21 to 50 in FY26). With maintenance capex of only about INR 1 crore a year between FY21 and FY25, free cash flow of INR 7–9 crore a year funded about INR 25 crore of debt reduction from FY19 to FY24 and the FY25 buyback. FY26 capex rose to INR 4.74 crore (CWIP INR 3 crore at year-end). This may relate to modernisation or the planned packaging line, but the purpose is not disclosed. It cut FCF to about INR 3 crore.
Ratio analysis
Zeros in the TD/GCA row (FY22–FY23) and the CARE operating-cycle row (FY22–FY23) mean "not disclosed in sources accessed". FY22 interest coverage is derived from Screener's rounded interest figure.
ROIC is not reported. As a proxy, after-tax ROCE was about 6–9% in FY24–FY26, using Screener ROCE and the reported tax rates.
Overall ratio commentary. Returns are below the cost of equity. ROE averaged 7.6–8% over three, five and ten years (Screener), against a cost of equity for an Indian micro-cap that is likely in the mid-teens. The driver is not leverage, which is modest and falling. It is low asset productivity: fixed-asset turnover of about 0.47x (CARE) because looms run at 40–60% utilisation. CARE's own upgrade triggers make the point. The company would need ROCE of at least 12% sustained, EBITDA margins above 20% and gearing below 0.30x to warrant a higher rating. Sustained ROCE below 5% or margins below 15% were downgrade triggers, and FY26 margins of 14.6% breached the latter. Interest coverage of about 7x and net debt/EBITDA of about 1.4x indicate low solvency risk.
7. SEGMENTAL AND GEOGRAPHIC REVENUE MAPPING
Segment × geography
There is one segment, so segment × geography collapses to the geographic split below. Country-level export revenue is not publicly disclosed.
Geographic revenue (INR Cr)
Sources: FY26 annual report as summarised by ScanX (exports INR 296.71 lakh vs INR 74.59 lakh). ScanX headlines the export increase as "+311%", which does not match these figures. The arithmetic gives +298%; the dossier uses the computed figure. Domestic revenue is derived. FY2024 export revenue is not available in sources accessed (Screener's "Export Revenue" field is behind a paywall).
Analysis. Arex is overwhelmingly a domestic supplier. Much of its "domestic" revenue, however, comes from Indian exporters (Welspun's home textiles and Tirupur knitwear), so it is indirectly exposed to US and EU retail demand. FY26 was the first year in which direct exports became meaningful. Domestic revenue fell 7.4% while direct exports rose fourfold to 6% of sales. Destination markets are not disclosed. The likely explanation is that Arex now ships labels directly to overseas garment makers (for example in Bangladesh or Sri Lanka) nominated by brands, but this is an inference and not confirmed by the company. The domestic decline is consistent with CARE's comment about softer demand in the garment-label sector. A breakdown between Welspun-linked and other domestic revenue is not disclosed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 53.75 | 45.02 | 51.01 | 51.14 | 49.64 |
Operating expenses (INR Cr; FY25–26 derived as revenue minus PBILDT) | 42.53 | 38.20 | 41.92 | 42.99 | 42.38 |
EBITDA / PBILDT (INR Cr; FY22 Screener, FY23–26 CARE) | 11.22 | 6.83 | 9.07 | 8.15 | 7.26 |
Other income (INR Cr) | 0.04 | 0.23 | 0.09 | 0.69 | 0.06 |
Depreciation (INR Cr; FY22–23 rounded) | 4 | 4 | 4.16 | 4.13 | 4.36 |
Finance costs (INR Cr; FY22–23 rounded) | 2 | 2 | 1.33 | 1.09 | 1.04 |
Profit before tax (INR Cr; FY22–23 derived from PAT and tax rate) | 4.68 | 1.01 | 3.70 | 3.67 | 1.92 |
Tax rate (%) | 21 | 31 | 31 | 28 | 23 |
Net profit / PAT (INR Cr; FY22 derived from EPS) | 3.70 | 0.70 | 2.54 | 2.63 | 1.48 |
EPS basic and diluted (INR) | 9.35 | 1.77 | 6.42 | 7.31 | 4.11 |
Dividend per share declared for the year (INR) | 0 | 0 | 0 | 0 | 2.50 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 20.9 | 15.2 | 17.8 | 15.9 | 14.6 |
PBT margin (%) | 8.7 | 2.2 | 7.3 | 7.2 | 3.9 |
Net margin (%) | 6.9 | 1.6 | 5.0 | 5.1 | 3.0 |
Dividend payout (%) | 0 | 0 | 0 | 0 | 61 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 11.68 | 12.80 | 13.05 | 13.48 | 12.97 | 12.34 | 13.20 | 12.64 | 11.27 | 13.01 | 12.99 | 12.38 | 14.28 |
Operating profit (INR Cr) | 1.86 | 2.40 | 3.52 | 1.32 | 2.49 | 1.37 | 2.58 | 1.76 | 1.70 | 2.63 | 1.52 | 1.40 | 3.36 |
OPM (%) | 15.92 | 18.75 | 26.97 | 9.79 | 19.20 | 11.10 | 19.55 | 13.92 | 15.08 | 20.22 | 11.70 | 11.31 | 23.53 |
Other income incl. exceptional (INR Cr) | 0.00 | 0.00 | 0.00 | 0.09 | 0.00 | 0.65 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.06 | 9.54 |
PBT (INR Cr) | 0.39 | 0.94 | 2.12 | 0.25 | 1.23 | 0.86 | 1.23 | 0.35 | 0.35 | 1.28 | 0.20 | 0.11 | 11.78 |
Net profit (INR Cr) | 0.28 | 0.77 | 1.47 | 0.03 | 0.83 | 0.57 | 0.98 | 0.26 | 0.25 | 1.00 | 0.26 | -0.03 | 8.81 |
EPS (INR) | 0.71 | 1.95 | 3.71 | 0.08 | 2.10 | 1.58 | 2.72 | 0.72 | 0.69 | 2.78 | 0.72 | -0.08 | 24.48 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr; derived from share count) | 3.96 | 3.96 | 3.96 | 3.60 | 3.60 |
Net worth (INR Cr; FY22–23 rounded Screener, FY24–26 CARE) | 28 | 29 | 31.61 | 25.67 | 27.74 |
Total borrowings (INR Cr; Screener rounded) | 23 | 18 | 10 | 12 | 11 |
Total debt (INR Cr; CARE gearing × net worth, FY23–26) | 0 | 17.7 | 10.4 | 12.3 | 10.5 |
Other liabilities (INR Cr; rounded) | 7 | 6 | 8 | 9 | 7 |
Total assets (INR Cr; FY25–26 audited) | 58 | 53 | 50 | 46.62 | 44.97 |
Net fixed assets (INR Cr; rounded) | 36 | 33 | 30 | 27 | 25 |
Capital work-in-progress (INR Cr; rounded) | 0 | 0 | 0 | 1 | 3 |
Other assets incl. inventory and receivables (INR Cr; rounded) | 22 | 19 | 20 | 19 | 17 |
Trade receivables (INR Cr) | 0 | 0 | 0 | 8.07 | 6.83 |
Goodwill and intangibles (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet and Financial Ratios (x)
| Metric | FY2025 | FY2026 |
|---|---|---|
Cash and cash equivalents (INR Cr) | 0.05 | 0.11 |
Current borrowings (INR Cr) | 7.09 | 10.60 |
Non-current borrowings (INR Cr) | 5.2 | 0 |
Net debt (INR Cr; derived) | 12.25 | 10.4 |
Current ratio (x; CARE) | 1.31 | 1.00 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operations (INR Cr; FY22–23 rounded, FY24–26 CARE) | 10 | 8 | 9.48 | 8.67 | 7.58 |
Cash from investing (INR Cr; FY26 audited) | -1 | -1 | -1 | -1 | -4.74 |
Cash from financing (INR Cr; rounded) | -10 | -7 | -9 | -8 | -3 |
Free cash flow (INR Cr; Screener) | 9 | 7 | 8 | 7 | 3 |
Share buyback (INR Cr; derived) | 0 | 0 | 0 | 7.02 | 0 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
CFO / operating profit (%) | 103 | 116 | 106 | 126 | 119 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROCE (%; Screener) | 13 | 6 | 11 | 12 | 8 |
ROE (%; derived, PAT / average net worth) | 14.0 | 2.5 | 8.4 | 9.2 | 5.5 |
ROA (%; derived, PAT / average total assets) | 6.1 | 1.3 | 4.9 | 5.4 | 3.2 |
Debt / equity (x; FY22 derived, FY23–26 CARE) | 0.82 | 0.61 | 0.33 | 0.48 | 0.38 |
Net debt / EBITDA (x; derived) | 2.0 | 2.6 | 1.15 | 1.51 | 1.43 |
Interest coverage, PBILDT / interest (x; FY23–26 CARE) | 5.6 | 3.76 | 6.83 | 7.45 | 6.98 |
Total debt / gross cash accruals (x; CARE) | 0 | 0 | 1.45 | 1.87 | 1.99 |
Asset turnover (x; derived, revenue / average total assets) | 0.89 | 0.81 | 0.99 | 1.06 | 1.08 |
Debtor days (Screener) | 64 | 66 | 68 | 58 | 50 |
Inventory days (Screener, COGS basis) | 229 | 235 | 192 | 195 | 197 |
Payable days (Screener) | 92 | 83 | 94 | 114 | 81 |
Cash conversion cycle (days; Screener) | 201 | 218 | 166 | 139 | 166 |
Operating cycle (days; CARE basis) | 0 | 0 | 105 | 93 | 98 |
Income Statement and Margin Analysis (%) (FY2025–FY2026)
| Region | FY2025 | FY2026 |
|---|---|---|
Domestic India revenue (INR Cr; derived) | 50.40 | 46.67 |
Export revenue (INR Cr) | 0.75 | 2.97 |
Total revenue from operations (INR Cr) | 51.14 | 49.64 |
Export share of revenue (%) | 1.5 | 6.0 |
Growth metric | FY2026 YoY % | — |
Domestic revenue growth | -7.4 | — |
Export revenue growth | 297.7 | — |
Total revenue growth | -2.9 | — |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last price | INR 128.50 (ScanX, accessed 19-Oct-2026); INR 127.00 (Screener close 25-Sep-2026) | ScanX; Screener |
52-week high / date | INR 165.70 / 1-Sep-2025 | Business Standard |
52-week low / date | INR 95.50 / 9-Apr-2026 | Business Standard |
All-time high / date | INR 314.70 / 20-Oct-2022 | Business Standard |
All-time low / date | INR 1.75 / 1-Feb-1999 | Business Standard |
6-month return | +18.4% (ScanX, Oct-2026) | ScanX |
Metric | 1Y | 3Y CAGR |
Stock price return (%; Screener, Sep-2026) | -18 | 3 |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
P/E, reported TTM | 4.6x | TTM PAT INR 10.04 crore including the exceptional gain (ScanX shows 4.41x) |
P/E, normalised TTM | About 15.9x | TTM PAT excluding the INR 9.54 crore exceptional gain (taxed at 25.3%) ≈ INR 2.91 crore; EPS about INR 8.1. Screener shows 15.2x. |
P/E, FY26 | 31.3x | FY26 EPS INR 4.11 |
P/B | 1.67x | FY26 net worth INR 27.74 crore; about 1.3x on post-Q1 FY27 book (estimated) |
EV / EBITDA, FY26 | 7.8x | EV ≈ INR 56.7 crore (market cap 46.3 + net debt 10.4) / EBITDA 7.26 |
EV / EBITDA, TTM | 6.4x | TTM operating profit INR 8.91 crore |
EV / Sales, TTM | 1.08x | TTM revenue INR 52.66 crore |
Dividend yield | 1.95% | INR 2.50 / INR 128.50 |
Dividend History
| Fiscal year | Dividend payout (%; Screener) | Dividend per share (INR) |
|---|---|---|
FY2015 | 13 | Not disclosed in sources accessed |
FY2016 | 41 | — |
FY2017 | 25 | — |
FY2018 | 23 | — |
FY2019 | 31 | 2.00 (20%, ex-date 6-Sep-2019) |
FY2020–FY2025 | 0 | 0 |
FY2026 | 61 | 2.50 (25%; record date 16-Sep-2026; outlay INR 89.97 lakh) |
“—” = not publicly disclosed.
Capital Programmes
| Programme | Size | Price | Record date | Status |
|---|---|---|---|---|
2024 tender-offer buyback | Up to 3,60,000 shares (about 9.1% of pre-buyback equity) | INR 195 | 7-Sep-2024 | Completed; extinguished by 7-Oct-2024; about INR 7.02 crore |
Credit Ratings
| Agency | Rating | Outlook | Date | Status |
|---|---|---|---|---|
CARE Ratings (CareEdge) | CARE BBB (long-term) / CARE A3+ (short-term) | Stable | 6-Jul-2026 | Reaffirmed and withdrawn at the company's request |
Moody's / S&P / Fitch | Not rated | — | — | — |
Capital Instruments
| Instrument | Amount (INR Cr) | Maturity | Status |
|---|---|---|---|
Term loan 1 | 0 | — | Fully repaid; No Dues Certificate received (CARE, Jul-2026) |
Term loan 2 | Not disclosed (part of current borrowings) | March 2027 | All outstanding term loans classified as current maturities in FY26 (CARE) |
Cash credit / working capital | Part of current borrowings of INR 10.60 crore (FY26) | Revolving | CARE-rated limit INR 5.50 crore (Jun-2025) |
Directors' unsecured loans | Withdrawn in FY26 (CARE) | — | — |
Timing Details
| Timing | Catalyst / monitorable | What to watch |
|---|---|---|
26 Oct 2026 | Q2 / H1 FY27 results | Whether revenue growth (+26.7% in Q1) and OPM above 20% persist; use of the INR 9.54 crore insurance proceeds; net debt at 30-Sep-2026 |
Jan 2027 | Q3 FY27 results | Employee-cost trend; export run-rate |
Mar 2027 | Final term-loan maturity | Debt-free status |
FY27 | Packaging-materials launch | Any capex, plant or first revenue disclosure |
May 2027 | FY27 audited results and dividend | Dividend sustainability; payout policy |
Ongoing | Welspun agreement | Any renewal or extension announcement before the roughly 2028 expiry |
Ongoing | Promoter pledge (SAST disclosures) | Release or increase of pledged shares |
Ongoing | US–India trade policy | Effect on home-textile and garment-export customers |
Executive Leadership
Board of Directors
| Name | Title | Tenure / status | Background | Age / birth year | DIN |
|---|---|---|---|---|---|
Dinesh Apparao Bilgi | Managing Director and CFO; founder promoter | Founder (1989). Reappointed as MD effective 1 Aug 2026 (36th AGM). | More than 30 years in woven-label manufacturing. Runs day-to-day operations (CARE). Described as a "technocrat" with weaving expertise. | Born 1952 (about 74) | 00,096,099 |
Neel Dinesh Bilgi | Managing Director (Sales and Marketing); promoter | Reappointed effective 1 Aug 2026 | Son of the founder. More than 15 years of industry experience (CARE). Signs most BSE filings. | Born 1978 (about 48) | 00,096,180 |
Chirag Dinesh Bilgi | Managing Director (Production and Technical); promoter | Reappointed effective 1 Aug 2026 | Son of the founder. More than 15 years of industry experience (CARE). | Born 1983 (about 43) | 02,094,970 |
Kairavi N. Bilgi | Company Secretary and Compliance Officer (KMP) | Since 1 Sep 2015 | Promoter family member (same surname, "N." initial; relationship not formally disclosed in sources accessed) | — | — |
Pragnesh K. Shah | Director (non-independent) | Retired by rotation and reappointed at 37th AGM (23-Sep-2026) | Classification conflicts across sources: one lists him as "Executive Director", others as non-executive. Retirement by rotation confirms he is non-independent. | — | — |
Laxman C. Tilani | Non-executive director (non-independent) | Retired by rotation and reappointed at 37th AGM | — | — | — |
Aviv J. Divekar | Non-executive Independent Director | Second and final five-year term, 1 Sep 2026 to 31 Aug 2031 (approved at 37th AGM) | — | — | — |
Manoj Shah | Non-executive director (per Enrichmoney listing) | — | — | — | — |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Assessment |
|---|---|
Chair / CEO separation | No CEO title is used. Three promoter family members are joint Managing Directors and the founder also holds the CFO role. Who chairs the board is not disclosed in sources accessed. |
Executive concentration | Three of the roughly six or seven directors are promoter executives from one family. The CFO function sits with the founder MD rather than an independent finance professional. |
Independence | At least one independent director (Aviv Divekar) is confirmed. The full count of independent directors required under SEBI LODR Reg. The FY26 ASCR reports no non-compliance, which implies the minimum composition was met. |
Committees | Audit Committee confirmed to have pre-approved all related-party transactions (ASCR FY26). Composition of the Nomination & Remuneration and Stakeholder Relationship Committees is not disclosed in sources accessed. |
Board evaluation | Performance evaluation of the board, independent directors and committees was conducted (ASCR FY26). |
Regulatory record | No actions by SEBI or BSE against the company, promoters or directors in FY26 (ASCR FY26). |
Succession | The second-generation MDs (aged about 43 and 48) are already in place, which reduces key-person risk around the 74-year-old founder. The maturity of a keyman insurance policy in Q1 FY27 (INR 9.54 crore) shows the company has insured that risk. |
Board & Management Changes
| Date | Change |
|---|---|
13 Aug 2025 | Board proposes reappointment of all three MDs (Dinesh, Neel and Chirag Bilgi) |
29 Sep 2025 | 36th AGM approves MD reappointments effective 1 Aug 2026 |
29 Jul 2026 | Board recommends second term for Independent Director Aviv Divekar |
23 Sep 2026 | 37th AGM approves Divekar's reappointment and the rotational reappointment of P.K. Shah and L.C. Tilani |
Shareholding Trend
| Holder category | Jun-2024 | Jun-2025 | Jun-2026 |
|---|---|---|---|
Promoters and promoter group (%) | 70.53 | 70.60 | 70.60 |
Public (%) | 29.46 | 29.38 | 29.39 |
DIIs (%) | 0 | 0 | 0 |
FIIs (%) | 0 | 0 | 0 |
Number of shareholders | 2,381 | 2,408 | 2,181 |
Governance Timeline
| Date | Initiative | Detail | Quantified targets |
|---|---|---|---|
Aug–Sep 2024 | Share buyback (tender offer) | Up to 3.6 lakh shares at INR 195; about INR 7.02 crore | Completed Oct 2024 |
13 Aug 2025 | Business expansion into packaging materials | Board approved alteration of the MoA objects clause, ratified at 36th AGM | Capex, timeline, revenue targets not disclosed |
FY2026 | Capex programme | INR 4.74 crore invested in property, plant and equipment; CWIP about INR 3 crore at FY26-end | Purpose not disclosed |
FY2026 | Export push | Exports up about four times to INR 2.97 crore | No target disclosed |
FY2026–Q1 FY27 | Deleveraging | Non-current borrowings fully repaid; one term-loan lender issued a No Dues Certificate; all remaining term loans due in FY27 | Debt-free target not stated |
6 Jul 2026 | Credit rating withdrawal | Requested by the company after lenders issued NOCs | Signals reduced reliance on rated bank debt |
May–Sep 2026 | Dividend resumption | INR 2.50 per share for FY26 (25% of face value) | No formal dividend policy disclosed |
Competitive Landscape
Key Competitors
| # | Competitor | Tier | Home base | Relevance to Arex |
|---|---|---|---|---|
| 1 | Avery Dennison (Solutions Group, formerly RBIS / Paxar) | Global | USA (NYSE: AVY) | Largest global apparel label and RFID supplier; Indian operations serve export garment makers |
| 2 | CCL Industries (CCL Design / Checkpoint Systems apparel labelling) | Global | Canada (TSX: CCL.B) | Woven and printed labels and RFID via Checkpoint (acquired 2016) |
| 3 | SML Group | Global | Hong Kong (private) | Woven and printed labels and RFID; India manufacturing |
| 4 | r-pac International | Global | USA (private) | Trims and labels for brands |
| 5 | Finotex | Global | Colombia / USA (private) | Woven labels and trims; Asian plants |
| 6 | Trimco International | Global | Hong Kong (private) | Labels and trims |
| 7 | ITL Group | Global | Hong Kong / UK (private) | Labels and RFID |
| 8 | Nilorn Group | Global / regional | Sweden (Nasdaq Stockholm) | Woven labels and branding; production in South Asia |
| 9 | Organised Indian woven-label converters (Tirupur / Bangalore / NCR clusters) | Domestic organised | India (mostly unlisted) | Direct competitors for domestic garment makers |
| 10 | Unorganised local weavers and printers | Domestic unorganised | India | Set the price floor; limit pass-through (CARE) |
| 11 | Customers' in-house label units (vertical integration) | Captive | India | Large home-textile and garment groups can insource labels |
Peer Comparison FY2026
| Metric | Arex Industries (FY26) | Avery Dennison (FY24) | CCL Industries (FY24) | SML Group |
|---|---|---|---|---|
Revenue | INR 49.64 crore (about USD 5.8 million) | About USD 8.8 billion (group) | About CAD 7.2 billion (group) | — |
Revenue growth | −2.9% | — | — | — |
EBITDA margin | 14.6% | — | — | — |
RFID / digital ID capability | None disclosed | Yes (market leader) | Yes (Checkpoint) | Yes |
Footprint | 2 plants, India only | Global | Global | Global |
“—” = not publicly disclosed.
Recent Developments
ScanX gave the 37th AGM date as 25 September 2026 in one headline. BSE filings confirm 23 September 2026.



